


ACB Trial – An International Pragmatic Trial of Thromboprophylaxis in Muscle-Invasive Bladder Cancer Patients during Neoadjuvant Chemotherapy



ACB

Thromboprophylaxis with Apixaban
During Neoadjuvant Chemotherapy for
Muscle-Invasive Bladder Cancer
A randomized trial by **CLUE**

STUDY DESIGN AND ELIGIBILITY

- Pragmatic trial of >440 patients in large hospitals in Finland, other Nordic countries and the UK
- Randomized, open-label
- Patients with muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy (NAC)

RANDOMIZATION

- Randomization (1:1) to apixaban or no anticoagulant for the duration of NAC (3–4 cycles, according to local standard of care)

FOLLOW-UP

- Six-month follow-up (from the start of NAC) for VTE and bleeding
- Long-term follow-up for mortality

Experimental Arm

Local standard of care +

Apixaban 2.5 mg twice daily for the duration of NAC

Comparator Arm

Local standard of care +

No anticoagulation

PRIMARY OUTCOME

- Incidence of venous thromboembolism (VTE) events detected on a routine CT scan after NAC

OTHER OUTCOMES

- Incidence of symptomatic VTEs
- Major bleeding
- Serious adverse events
- Time from NAC to radical surgery or chemoradiotherapy
- Cost-effectiveness
- Survival